Results 1 to 10 of about 272,115 (210)

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization

Biomolecules
Despite extensive use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) biologics for over a decade, neovascular age-related macular degeneration (nAMD) or choroidal neovascularization (CNV) continues to be a major cause of irreversible
Yingbin Fu, Zhao Zhang, Keith A. Webster, Yannis M. Paulus   +3 more
doaj   +3 more sources

Anti-VEGF Treatments and Marketing. [PDF]

Rom J Ophthalmol
Gheorghe CM.
europepmc   +3 more sources

Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors

Computational and Systems Oncology, 2021
Vascular endothelial growth factor (VEGF) is a strong promoter of angiogenesis in tumors, and anti‐VEGF treatment, such as a humanized antibody to VEGF, is clinically used as a monotherapy or in combination with chemotherapy to treat cancer patients ...
Ding Li, Stacey D. Finley
doaj   +1 more source

Effect of Alternate Treatment with Intravitreal Corticosteroid and Anti-VEGF for Macular Edema Secondary to Retinal Vein Occlusion

Journal of Ophthalmology, 2021
Purpose. To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO). Methods.
Young Hwan Bae, Seong Mi Kim, Jin Young Kim, So Hyun Bae, Hakyoung Kim, Dae Joong Ma   +5 more
doaj   +1 more source

Anti-VEGF drugs: evidence for effectiveness

Community Eye Health Journal, 2014
Anti-vascular endothelial growth factors (anti-VEGF) are targeted biological drugs (e.g. monoclonal antibodies) that prevent the growth of new vessels by inhibiting VEGF.
Jennifer Evans , Gianni Virgili
doaj   +2 more sources

Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials

BMJ Open, 2023
Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria.Data sources PubMed ...
Chao Zhang, Jie Bai, Liming Dong, Xiao Cheng, Zhihui Song, Guangyao Li   +5 more
doaj   +1 more source

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF

Journal of Ophthalmology, 2021
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns.
Di Zou, Imran Jawaid, Winfried M. Amoaku
doaj   +1 more source

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy

Annals of Medicine, 2022
Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes mellitus, representing a major cause of visual impairment in developed countries.
Alessandro Arrigo, Emanuela Aragona, Francesco Bandello   +2 more
doaj   +1 more source

Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Scientific Reports, 2021
We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy ...
Keiichiro Tanaka, Yasuharu Oguchi, Tomoko Omori, Yumi Ishida, Hiroaki Shintake, Ryutaro Tomita, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, Kanako Itagaki, Akira Ojima, Takeshi Machida, Hideharu Sekine, Tetsuju Sekiryu   +13 more
doaj   +1 more source

Future of anti-VEGF: biosimilars and biobetters [PDF]

International Journal of Retina and Vitreous, 2022
AbstractThe advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO).
Monika Kapur, Suvansh Nirula, Mayuresh P. Naik   +2 more
openaire   +3 more sources